Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines for people with serious diseases in the United States. Its pipeline includes programs in hematology and genetic disease, such as Ristoglogene autogetemcel, a patient-specific autologous hematopoietic stem cell therapy being developed for sickle cell disease, along with BEAM-302 for severe alpha-1 antitrypsin deficiency, BEAM-304 for phenylketonuria, and BEAM-301 for glycogen storage disease type 1a. The company is also advancing the ESCAPE platform, which combines antibody-based conditioning with multiplex gene-edited HSCs, and BEAM-103, an anti-CD117 monoclonal antibody designed to enable ESCAPE. Beam Therapeutics maintains research collaborations with Pfizer, Verve Therapeutics, and Orbital Therapeutics. Incorporated in 2017, the company is based in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BEAM
|
$26.81
|
-1.7% Downside
|
Fair
|
$52.31
|
91.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-41.5x
|
2.4x
|
16.7x
|
2.621 B
|
1.777 B
|
8.7%
|
88.3%
|
3.6
|
—
|
581.8%
|
